Pharmacotherapy Follow-up in Older HIV-infected Patients
Pharmacotherapy Follow-up in Older HIV-infected Patients: Impact on Cardiovascular Risk and Quality of Life
Cardiovascular diseases (CVD) are the main cause of death in Spain. In HIV patients, the uncontrolled viral replication, antiretroviral therapy (ART) and coinfections contribute to develop metabolic diseases and increase the prevalence of risk factors for CVD. These patients are aging which results in a higher probability of comorbidities, increased number of medications, possibility of having a negative outcome associated with medication (NOM) and increased cardiovascular risk (CVR). Various studies have established that pharmaceutical care (PC) results in better control of cardiovascular risk factors.
The purpose of this study is to evaluate the impact of pharmaceutical care achieved through pharmacotherapy follow-up on cardiovascular risk and health related quality of life (HRQoL) of HIV patients older than 50.
Studieöversikt
Detaljerad beskrivning
Quasi-experimental clinical study, pre-post intervention, performed with one patient cohort.
Study will be carry out at a tertiary hospital. The population will be constituted of patients who receive care from the outpatient department of the pharmacy service in use of antiretroviral therapy.
Variables will be obtained from patients' clinical histories, from dispensing records and through interviews with patients.
Main variables:
- cardiovascular risk estimated according to Systematic Coronary Risk Evaluation (SCORE) and Registre Gironí del Cor (REGICOR) equations
- HRQoL measured by the Short-Form 36-Item Health Survey (SF-36) and Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaires.
Other variables: sociodemographic, clinical, pharmacological, related to CVR, related to NOM and to the interventions.
Interventions will be performed every two months until complete 12 months of follow-up. Pharmacotherapy follow-up will be conducted according to the Dader method. The interventions will be health education for lifestyle modification, improve adherence and aimed to the resolution of NOM and drug-related problems.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Granada, Spanien
- Hospital Universitario Virgen de las Nieves
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- patients older than 50 years
- in use of antiretroviral therapy
- cardiovascular risk ≥2%, estimated by the SCORE equation
- accept to participate in the research through the signature of a written informed consent
Exclusion Criteria:
- patients with neurodegenerative deficit or HIV dementia
- participants in clinical trials
- non signature of a written informed consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Pharmaceutical care
Dader method.
Health education for lifestyle modification.
Improve adherence.
Resolution of negative outcome associated with medication.
|
This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cardiovascular risk estimation
Tidsram: Baseline and 12 months
|
Change in cardiovascular risk estimated by SCORE equation will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Cardiovascular risk estimation
Tidsram: Baseline and 12 months
|
Change in cardiovascular risk estimated by REGICOR equation will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Health-related quality of life
Tidsram: Baseline and 12 months
|
Change in health-related quality of life measured by SF-36 questionnaire will be evaluated after one year of Pharmaceutical Care.
|
Baseline and 12 months
|
|
Health-related quality of life
Tidsram: Baseline and 12 months
|
Change in health-related quality of life measured by MOS-HIV questionnaire will be evaluated after one year of Pharmaceutical Care.
|
Baseline and 12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Systolic and diastolic blood pressure
Tidsram: Baseline and 12 months
|
Change in systolic and diastolic blood pressure will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Total cholesterol levels
Tidsram: Baseline and 12 months
|
Change in total cholesterol levels will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
High-density lipoprotein (HDL-c) levels
Tidsram: Baseline and 12 months
|
Change in HDL-c will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Low-density lipoprotein (LDL-c) levels
Tidsram: Baseline and 12 months
|
Change in LDL-c will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Triglycerides levels
Tidsram: Baseline and 12 months
|
Change in triglycerides levels will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Glucose levels
Tidsram: Baseline and 12 months
|
Change in glucose levels will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
|
Number of patients with smoking cessation
Tidsram: Baseline and 12 months
|
Patients that achieve smoking cessation after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Elza Aparecida M Domingues, MSc, Universidad de Granada
- Studierektor: Miguel Angel Calleja Hernandez, PhD, University Hospital Virgen de las Nieves
- Studierektor: Monica Ferrit Martin, PhD, University Hospital Virgen de las Nieves
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- University of Granada
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .